SPC
CRSP icon

Sigma Planning Corp’s CRISPR Therapeutics CRSP Stock Holding History

Sigma Planning Corp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,861
Closed -$209K – 1225
2024
Q2 		$209K Buy
+3,861
New +$223K 0.01% 1069
2022
Q4 		– Sell
-3,918
Closed -$256K – 1286
2022
Q3 		$256K Sell
3,918
-849
-18% -$61.5K 0.01% 1002
2022
Q2 		$290K Buy
+4,767
New +$280K 0.01% 1006
2021
Q4 		– Sell
-2,472
Closed -$277K – 1403
2021
Q3 		$277K Buy
2,472
+209
+9% +$26.2K 0.01% 1099
2021
Q2 		$366K Buy
+2,263
New +$275K 0.01% 980

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Sigma Planning Corp's CRSP Position: Q3 2024 in Review

Sigma Planning Corp sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 3,861 shares — an estimated $209K sold.

Sigma Planning Corp first reported a position in CRSP in Q2 2021 and held it in 5 quarters. The position peaked at $366K in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Sigma Planning Corp reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sigma Planning Corp sold 3,861 CRISPR Therapeutics shares in Q3 2024, an estimated $209K.
  • Sigma Planning Corp first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 5 quarters.
  • Sigma Planning Corp's CRISPR Therapeutics position peaked at $366K in Q2 2021.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Sigma Planning Corp's 13F filing for Q3 2024, filed 4 Nov 2024.